FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2769453207> ?p ?o ?g. }

• W2769453207 endingPage "375" @default.
• W2769453207 startingPage "364" @default.
• W2769453207 abstract "Background: In nonrandomized, open-label studies, a transcatheter interatrial shunt device (IASD, Corvia Medical) was associated with lower pulmonary capillary wedge pressure (PCWP), fewer symptoms, and greater quality of life and exercise capacity in patients with heart failure (HF) and midrange or preserved ejection fraction (EF ≥40%). We conducted the first randomized sham-controlled trial to evaluate the IASD in HF with EF ≥40%. Methods: REDUCE LAP-HF I (Reduce Elevated Left Atrial Pressure in Patients With Heart Failure) was a phase 2, randomized, parallel-group, blinded multicenter trial in patients with New York Heart Association class III or ambulatory class IV HF, EF ≥40%, exercise PCWP ≥25 mm Hg, and PCWP-right atrial pressure gradient ≥5 mm Hg. Participants were randomized (1:1) to the IASD versus a sham procedure (femoral venous access with intracardiac echocardiography but no IASD placement). The participants and investigators assessing the participants during follow-up were blinded to treatment assignment. The primary effectiveness end point was exercise PCWP at 1 month. The primary safety end point was major adverse cardiac, cerebrovascular, and renal events at 1 month. PCWP during exercise was compared between treatment groups using a mixed-effects repeated measures model analysis of covariance that included data from all available stages of exercise. Results: A total of 94 patients were enrolled, of whom 44 met inclusion/exclusion criteria and were randomized to the IASD (n=22) and control (n=22) groups. Mean age was 70±9 years, and 50% were female. At 1 month, the IASD resulted in a greater reduction in PCWP compared with sham control ( P =0.028 accounting for all stages of exercise). Peak PCWP decreased by 3.5±6.4 mm Hg in the treatment group versus 0.5±5.0 mm Hg in the control group ( P =0.14). There were no peri-procedural or 1-month major adverse cardiac, cerebrovascular, and renal events in the IASD group and 1 event (worsening renal function) in the control group ( P =1.0). Conclusions: In patients with HF and EF ≥40%, IASD treatment reduces PCWP during exercise. Whether this mechanistic effect will translate into sustained improvements in symptoms and outcomes requires further evaluation. Clinical Trial Registration: URL: https://clinicaltrials.gov . Unique identifier: NCT02600234." @default.
• W2769453207 created "2017-12-04" @default.
• W2769453207 creator A5002451590 @default.
• W2769453207 creator A5008596377 @default.
• W2769453207 creator A5009535057 @default.
• W2769453207 creator A5018149893 @default.
• W2769453207 creator A5027983406 @default.
• W2769453207 creator A5039800294 @default.
• W2769453207 creator A5043143051 @default.
• W2769453207 creator A5044456502 @default.
• W2769453207 creator A5046319923 @default.
• W2769453207 creator A5052844560 @default.
• W2769453207 creator A5056345963 @default.
• W2769453207 creator A5056564907 @default.
• W2769453207 creator A5058639023 @default.
• W2769453207 creator A5066070606 @default.
• W2769453207 creator A5073215541 @default.
• W2769453207 creator A5077892878 @default.
• W2769453207 creator A5081743465 @default.
• W2769453207 creator A5083109907 @default.
• W2769453207 date "2018-01-23" @default.
• W2769453207 modified "2023-10-18" @default.
• W2769453207 title "Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure])" @default.
• W2769453207 cites W1765042860 @default.
• W2769453207 cites W1966482221 @default.
• W2769453207 cites W1991463267 @default.
• W2769453207 cites W2057547167 @default.
• W2769453207 cites W2073069044 @default.
• W2769453207 cites W2080053058 @default.
• W2769453207 cites W2098232644 @default.
• W2769453207 cites W2103313207 @default.
• W2769453207 cites W2109281287 @default.
• W2769453207 cites W2110392728 @default.
• W2769453207 cites W2129152730 @default.
• W2769453207 cites W2131242867 @default.
• W2769453207 cites W2133088349 @default.
• W2769453207 cites W2137784332 @default.
• W2769453207 cites W2156220725 @default.
• W2769453207 cites W2158510636 @default.
• W2769453207 cites W2159700625 @default.
• W2769453207 cites W2160839942 @default.
• W2769453207 cites W2283716994 @default.
• W2769453207 cites W2311933573 @default.
• W2769453207 cites W2472866729 @default.
• W2769453207 cites W2552276063 @default.
• W2769453207 cites W2574676500 @default.
• W2769453207 cites W2596803679 @default.
• W2769453207 cites W2601336993 @default.
• W2769453207 cites W2624239090 @default.
• W2769453207 cites W2765719257 @default.
• W2769453207 doi "https://doi.org/10.1161/circulationaha.117.032094" @default.
• W2769453207 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29142012" @default.
• W2769453207 hasPublicationYear "2018" @default.
• W2769453207 type Work @default.
• W2769453207 sameAs 2769453207 @default.
• W2769453207 citedByCount "193" @default.
• W2769453207 countsByYear W27694532072017 @default.
• W2769453207 countsByYear W27694532072018 @default.
• W2769453207 countsByYear W27694532072019 @default.
• W2769453207 countsByYear W27694532072020 @default.
• W2769453207 countsByYear W27694532072021 @default.
• W2769453207 countsByYear W27694532072022 @default.
• W2769453207 countsByYear W27694532072023 @default.
• W2769453207 crossrefType "journal-article" @default.
• W2769453207 hasAuthorship W2769453207A5002451590 @default.
• W2769453207 hasAuthorship W2769453207A5008596377 @default.
• W2769453207 hasAuthorship W2769453207A5009535057 @default.
• W2769453207 hasAuthorship W2769453207A5018149893 @default.
• W2769453207 hasAuthorship W2769453207A5027983406 @default.
• W2769453207 hasAuthorship W2769453207A5039800294 @default.
• W2769453207 hasAuthorship W2769453207A5043143051 @default.
• W2769453207 hasAuthorship W2769453207A5044456502 @default.
• W2769453207 hasAuthorship W2769453207A5046319923 @default.
• W2769453207 hasAuthorship W2769453207A5052844560 @default.
• W2769453207 hasAuthorship W2769453207A5056345963 @default.
• W2769453207 hasAuthorship W2769453207A5056564907 @default.
• W2769453207 hasAuthorship W2769453207A5058639023 @default.
• W2769453207 hasAuthorship W2769453207A5066070606 @default.
• W2769453207 hasAuthorship W2769453207A5073215541 @default.
• W2769453207 hasAuthorship W2769453207A5077892878 @default.
• W2769453207 hasAuthorship W2769453207A5081743465 @default.
• W2769453207 hasAuthorship W2769453207A5083109907 @default.
• W2769453207 hasBestOaLocation W27694532071 @default.
• W2769453207 hasConcept C126322002 @default.
• W2769453207 hasConcept C146556889 @default.
• W2769453207 hasConcept C164705383 @default.
• W2769453207 hasConcept C168563851 @default.
• W2769453207 hasConcept C203092338 @default.
• W2769453207 hasConcept C2778198053 @default.
• W2769453207 hasConcept C71924100 @default.
• W2769453207 hasConcept C78085059 @default.
• W2769453207 hasConcept C84393581 @default.
• W2769453207 hasConceptScore W2769453207C126322002 @default.
• W2769453207 hasConceptScore W2769453207C146556889 @default.
• W2769453207 hasConceptScore W2769453207C164705383 @default.
• W2769453207 hasConceptScore W2769453207C168563851 @default.
• W2769453207 hasConceptScore W2769453207C203092338 @default.
• W2769453207 hasConceptScore W2769453207C2778198053 @default.

• next